ClinicalTrials.gg
Sign In
TerminatedNCT00881283Updated Sep 2, 2020

Long-term Cardiovascular Risk in Cured Cushing's Patients

An observational study in Cushing's Disease, sponsored by Massachusetts General Hospital. Terminated at 1 site in United States. Open to female participants aged 35 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-09-02.

Sponsored by Massachusetts General Hospital · Observational

Why this study was terminated
Decision made to close study early.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
1
Ages
35 Years to 55 Years
Sex
Female
01

Study summary

The purpose of this study is to determine whether subjects who have been affected by Cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.

02

Conditions studied

  • Cushing's Disease

Keywords

  • Cushing's disease
03

In context

Pituitary ACTH Hypersecretion

64 studies on the registry are indexed under Pituitary ACTH Hypersecretion; 16 are open to participants now.

This study's enrollment of 1 is below the median of 131 across 20 observational studies indexed under Pituitary ACTH Hypersecretion.

Browse Pituitary ACTH Hypersecretion studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.

Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Browse Massachusetts General Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Cured Cushing's disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who have been cured of Cushing's disease at least 5 years ago.

Exclusion criteria

Exclusion Criteria:

  • patients who have been cured of Cushing's disease more than 15 years ago.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
1 participant (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • cured Cushing's disease
06

What researchers measure

Primary outcomes

  1. adipokine measurements

    Time frame: baseline

07

Study locations

1 site
  • Neuroendocrine Clinical Center
    Boston, Massachusetts 02114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2008 to primary completion in Mar 2010, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2009
First posted
Apr 15, 2009
StartActual
Sep 8, 2008
Primary completionActual
Mar 30, 2010
CompletionActual
Mar 30, 2010
Last update
Sep 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00881283
Lead sponsor
Massachusetts General Hospital
Responsible party
Karen Klahr Miller, MD (Chief, Neuroendocrine Unit, Massachusetts General Hospital) — Principal investigator
First posted
Apr 15, 2009
Start date
Sep 8, 2008
Primary completion
Mar 30, 2010
Completion
Mar 30, 2010
Last update
Sep 2, 2020

Study contacts

Anne Klibanski, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pituitary ACTH Hypersecretion →

Other studies from this sponsor

Massachusetts General Hospital →

Start the discussion